Eventide Asset Management - AMYLYX PHARMACEUTICALS INC ownership

AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 156 filers reported holding AMYLYX PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of AMYLYX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$20,449,285
-15.1%
1,116,8370.0%0.37%
-9.6%
Q2 2023$24,090,174
+79.3%
1,116,837
+143.8%
0.41%
+64.8%
Q1 2023$13,439,304
+45.5%
458,054
+83.2%
0.25%
+35.7%
Q4 2022$9,237,500250,0000.18%
Other shareholders
AMYLYX PHARMACEUTICALS INC shareholders Q2 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 2,515,868$46,065,54315.30%
Alpha Wave Global, LP 853,262$15,623,2279.88%
Saturn V Capital Management LP 886,143$16,225,2786.79%
Ally Bridge Group (NY) LLC 272,690$4,992,9545.86%
Altium Capital Management LP 534,700$9,790,3575.11%
Boxer Capital, LLC 2,084,000$38,158,0402.03%
Octagon Capital Advisors LP 695,000$12,725,4501.96%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 295,000$5,398,5001.82%
Tri Locum Partners LP 282,862$5,179,2031.66%
Perceptive Advisors 2,688,873$49,233,2651.64%
View complete list of AMYLYX PHARMACEUTICALS INC shareholders